HC Wainwright Expects Increased Earnings for Krystal Biotech

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Krystal Biotech to $6.83 (from $5.78), reiterated a Buy rating with a $310 target, and several other analysts also lifted price targets, leaving a consensus average near $324.11.
• Krystal posted a Q1 beat — EPS $1.83 vs. $1.45 expected and revenue $116.4M vs. $112.1M — with management citing Vyjuvek uptake and international expansion as drivers of ~32% revenue growth and profitable margins.
• Valuation and insider activity pose near-term risks: insiders sold about 129,164 shares (~$34.5M) in the last 90 days and the stock trades at roughly a 38× P/E, which could invite profit-taking despite positive results.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Research analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Krystal Biotech in a research report issued to clients and investors on Monday, May 4th. HC Wainwright analyst J. Pantginis now expects that the company will earn $6.83 per share for the year, up from their previous forecast of $5.78. HC Wainwright currently has a "Buy" rating and a $310.00 target price on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $7.58 per share. HC Wainwright also issued estimates for Krystal Biotech's FY2027 earnings at $6.66 EPS and FY2028 earnings at $11.80 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million.

KRYS has been the subject of several other reports. Chardan Capital upped their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. Jefferies Financial Group upped their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. Guggenheim upped their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. Evercore reaffirmed an "outperform" rating and set a $300.00 price objective on shares of Krystal Biotech in a report on Tuesday. Finally, Citigroup upped their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a "buy" rating in a report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $324.11.

Krystal Biotech Trading Down 0.8%

NASDAQ KRYS opened at $284.57 on Wednesday. The company has a fifty day simple moving average of $262.18 and a 200 day simple moving average of $247.15. The company has a market cap of $8.38 billion, a P/E ratio of 38.04 and a beta of 0.50. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $303.00.

Insider Activity at Krystal Biotech

In related news, Director Daniel Janney sold 37,895 shares of the company's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $266.88, for a total transaction of $10,113,417.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dino A. Rossi sold 18,950 shares of Krystal Biotech stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the sale, the director owned 78,691 shares in the company, valued at $20,570,614.31. This represents a 19.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 129,164 shares of company stock valued at $34,538,578 in the last 90 days. 13.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently bought and sold shares of the business. UMB Bank n.a. increased its holdings in Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company's stock valued at $36,000 after buying an additional 37 shares during the period. Optimize Financial Inc increased its holdings in Krystal Biotech by 1.4% in the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company's stock valued at $704,000 after buying an additional 40 shares during the period. Perigon Wealth Management LLC increased its holdings in Krystal Biotech by 0.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company's stock valued at $2,211,000 after buying an additional 41 shares during the period. Regal Investment Advisors LLC increased its holdings in Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company's stock valued at $1,075,000 after buying an additional 44 shares during the period. Finally, Torray Investment Partners LLC increased its holdings in Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company's stock valued at $3,108,000 after buying an additional 47 shares during the period. Institutional investors own 86.29% of the company's stock.

More Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q1 beat — Krystal reported EPS of $1.83 vs. $1.45 expected and revenue of $116.4M, topping estimates and showing profitable growth that supports near-term earnings visibility. Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
• Positive Sentiment: Product momentum — Management cited Vyjuvek uptake and international expansion as the primary driver of ~32% revenue growth, underpinning near-term revenue cadence and optionality from global launches. Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
• Positive Sentiment: Analyst upgrades and estimates raised — Several analysts increased forecasts after the results; HC Wainwright raised quarterly EPS estimates and maintains a Buy rating with a $310 target, which signals continued analyst confidence. Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
• Neutral Sentiment: Pipeline catalysts ahead — Management and coverage note multiple data readouts and program milestones planned through 2026, offering upside if readouts are positive but also creating binary event risk. Krystal Biotech posts strong Q1, eyes 6 data readouts in 2026
• Neutral Sentiment: Earnings call takeaways — Company highlighted “profitable growth” and reiterated commercial execution metrics; investors should watch cadence on gross margin and international rollout timing. Krystal Biotech Earnings Call Highlights Profitable Growth
• Negative Sentiment: Valuation and recent run-up create near-term headwinds — Coverage discussing valuation after the rally highlights that the stock’s premium multiples and recent strong gains may invite profit-taking and cap upside until further clinical/commercial proof points arrive. A Look At Krystal Biotech (KRYS) Valuation After Recent Share Price Momentum

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.